EPO and perinatal asphyxia: Phase III trials are under way to determine whether high-dose erythropoietin in conjunction with hypothermia in infants with moderate/severe HIE reduces the combined outcome of death or neurodevelopmental disability and improves neurodevelopmental outcomes at 2 years of age, without significant adverse effects, when compared with hypothermia alone71.